Emergent cuts 300 jobs and shuts down two facilities in cost-cutting drive
VaccineDrug ApprovalExecutive Change
Preview
Source: Pharmaceutical Technology
Shares in the biotech are currently down around 98.5% compared to highs in August 2020, when plans for the manufacturing of potential vaccines and Covid-19 therapeutics were in full swing. Image credit: GettyImages/SAUL LOEB.
Emergent BioSolutions has initiated the next phase of its cost-saving plan as the struggling biopharma aims to turnaround financial performance.
The company will lay off around 300 employees, along with the elimination of approximately 85 positions.
Shares in the biotech are currently down around 98.5% compared to highs in August 2020, when plans for the manufacturing of potential vaccines and Covid-19 therapeutics were in full swing. Most of the company’s sales come through its Narcan (naloxone) nasal spray and anthrax vaccines. The company also garnered success during the Covid-19 pandemic when it helped manufacture vaccines.
However, a cross-contamination issue, noted in 2021, meant Emergent was instructed by the US Food and Drug Administration (FDA) to discard or destroy up to an estimated 400 million doses worth of the key component used in vaccines by Johnson & Johnson and AstraZeneca. The fallout from the controversy coupled with weakening sales meant Emergent needed to install a new operational plan to improve profitability.
See Also:Magazine: Anticipation rises for RSV rollout as positive data emerges
Preview
Source: Pharmaceutical Technology
GRN-300 by Greenfire Bio for Triple-Negative Breast Cancer (TNBC): Likelihood of Approval
Preview
Source: Pharmaceutical Technology
Last August, the company pushed its CDMO business to one side to focus on its core businesses of medical countermeasures and Narcan. Around 400 employees were also laid off during this time.
The sweeping changes laid out by CEO Joe Papa are expected to save the company $80m a year. Emergent will take an initial hit of between $18m and $21m to fully implement the restructuring plan.
Papa said in a statement: “We have put in place a multi-year plan to position Emergent for sustainable and long-term success, and that starts by stabilising our operations, strengthening our balance sheet and managing our debt.”
Papa added that “Decisions like these are never easy” and that Emergent is “committed to providing resources to those affected as they transition to new opportunities”.
Emergent hired Joe Papa in February 2024 to turn around the fortunes of the company. Papa was previously CEO of Canadian drugmaker Bausch Health Companies (formerly Valeant Pharmaceuticals). With Papa at the helm, Valeant managed to pay off more than $6bn of debt.
Despite financial issues, Emergent has had some regulatory success in the past year. The biotech won full FDA approval for its anthrax vaccine Cyfendus and entered a five-year contract with the US Department of Defense to supply the vaccine to the US military. The deal, signed in January this year, is worth up to $235.8m.
In March 2023, Emergent won over-the-counter approval for its Narcan nasal spray, increasing accessibility to the opioid-overdose reversal medicine. In the same month, Emergent sold its travel vaccine portfolio to Bavarian Nordic in a deal that could rise in value to $384m.
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Indications
Targets
-Drugs
Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.